201 related articles for article (PubMed ID: 6987993)
1. The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia.
Schwandt P; Weisweiler P
Atherosclerosis; 1980 Mar; 35(3):301-6. PubMed ID: 6987993
[TBL] [Abstract][Full Text] [Related]
2. The effect of beta-pyridylcarbinol on lipoprotein lipids in primary type IIa hyperlipoproteinemia.
Schwandt P; Weisweiler P; Neureuther G
Atherosclerosis; 1979 Sep; 34(1):35-9. PubMed ID: 227427
[TBL] [Abstract][Full Text] [Related]
3. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
[TBL] [Abstract][Full Text] [Related]
4. Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients.
Weisweiler P; Schwandt P
Atherosclerosis; 1981 Apr; 39(1):45-9. PubMed ID: 7247989
[TBL] [Abstract][Full Text] [Related]
5. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774
[TBL] [Abstract][Full Text] [Related]
6. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
7. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
9. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
10. The effect of cholestyramine on lipoprotein lipids in patients with primary type IIA hyperlipoproteinemia.
Weisweiler P; Neureuther G; Schwandt P
Atherosclerosis; 1979 Jul; 33(3):295-300. PubMed ID: 226105
[TBL] [Abstract][Full Text] [Related]
11. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
Hutt V; Klör HU; Wechsler JG; Ditschuneit H
J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
[TBL] [Abstract][Full Text] [Related]
12. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
[TBL] [Abstract][Full Text] [Related]
13. Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Prager R; Schernthaner G; Kostner GM; Mühlhauser I; Zechner R; Dorda W
Atherosclerosis; 1982 Jun; 43(2-3):321-7. PubMed ID: 6810904
[TBL] [Abstract][Full Text] [Related]
14. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
[TBL] [Abstract][Full Text] [Related]
15. Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles.
Brousseau T; Clavey V; Bard JM; Fruchart JC
Clin Chem; 1993 Jun; 39(6):960-4. PubMed ID: 8504564
[TBL] [Abstract][Full Text] [Related]
16. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
[TBL] [Abstract][Full Text] [Related]
17. Serum lipoprotein composition in different types of hyperlipoproteinemia.
Carlson LA
Adv Exp Med Biol; 1975; 63():185-99. PubMed ID: 173148
[TBL] [Abstract][Full Text] [Related]
18. [Quantitative analysis of lipoproteins in hyperlipoproteinemias of type IIa, IIb and IV (author's transl)].
Loeper J; Goy-Loeper J; Rouffy J
Clin Chim Acta; 1979 Oct; 98(1-2):19-26. PubMed ID: 227624
[TBL] [Abstract][Full Text] [Related]
19. Influence of polyunsaturated fats and fat restriction on serum lipoproteins in humans.
Weisweiler P; Janetschek P; Schwandt P
Metabolism; 1985 Jan; 34(1):83-7. PubMed ID: 3965863
[TBL] [Abstract][Full Text] [Related]
20. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
